Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20.8M
-
Number of holders
-
125
-
Total 13F shares, excl. options
-
142M
-
Shares change
-
+6.19M
-
Total reported value, excl. options
-
$84.6M
-
Value change
-
+$3.89M
-
Put/Call ratio
-
5.78
-
Number of buys
-
45
-
Number of sells
-
-65
-
Price
-
$0.60
Significant Holders of Nektar Therapeutics - Common Stock, par value $0.0001 per share (NKTR) as of Q3 2023
153 filings reported holding NKTR - Nektar Therapeutics - Common Stock, par value $0.0001 per share as of Q3 2023.
Nektar Therapeutics - Common Stock, par value $0.0001 per share (NKTR) has 125 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 142M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (18.7M shares), Deep Track Capital, LP (18.4M shares), VANGUARD GROUP INC (12.1M shares), BlackRock Inc. (7.68M shares), ACADIAN ASSET MANAGEMENT LLC (7.63M shares), PRIMECAP MANAGEMENT CO/CA/ (7.2M shares), D. E. Shaw & Co., Inc. (6.12M shares), CITADEL ADVISORS LLC (5.63M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (4.9M shares), and Monaco Asset Management SAM (4.81M shares).
This table shows the top 125 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.